{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:10:14Z","timestamp":1792807814844,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To assess the diagnostic performance of Ultrasound Attenuation Analysis (USAT) in the diagnosis and grading of hepatic steatosis in patients with non-alcoholic fatty liver disease (NAFLD) using Controlled Attenuation Parameters (CAP) as a reference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>From February 13, 2023, to September 26, 2023, participants underwent CAP and USAT examinations on the same day. We used manufacturer-recommended CAP thresholds to categorize the stages of hepatic steatosis: stage 1 (mild) \u2212\u2009240 dB\/m, stage 2 (moderate) \u2212\u2009265 dB\/m, stage 3 (severe) \u2212\u2009295 dB\/m. Receiver Operating Characteristic curves were employed to evaluate the diagnostic accuracy of USAT and determine the thresholds for different levels of hepatic steatosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Using CAP as the reference, we observed that the average USAT value increased with the severity of hepatic steatosis, and the differences in USAT values among the different hepatic steatosis groups were statistically significant (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). There was a strong positive correlation between USAT and CAP (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.674,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). When using CAP as the reference, the optimal cut-off values for diagnosing and predicting different levels of hepatic steatosis with USAT were as follows: the cut-off value for excluding the presence of hepatic steatosis was 0.54 dB\/cm\/MHz (AUC 0.96); for mild hepatic steatosis, it was 0.59 dB\/cm\/MHz (AUC 0.86); for moderate hepatic steatosis, it was 0.73 dB\/cm\/MHz (AUC 0.81); and for severe hepatic steatosis, it was 0.87 dB\/cm\/MHz (AUC 0.87).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>USAT exhibits strong diagnostic performance for hepatic steatosis and shows a high correlation with CAP values.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-024-03160-8","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T03:02:38Z","timestamp":1708657358000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Comparative study of ultrasound attenuation analysis and controlled attenuation parameter in the diagnosis and grading of liver steatosis in non-alcoholic fatty liver disease patients"],"prefix":"10.1186","volume":"24","author":[{"given":"Mengyun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzhen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijie","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baishan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fajin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"3160_CR1","doi-asserted-by":"crossref","unstructured":"Younossi ZM, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Volume 64. Hepatology (Baltimore, Md.),; 2016. pp. 73\u201384. 1.","DOI":"10.1002\/hep.28431"},{"issue":"4","key":"3160_CR2","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/hep.30702","volume":"70","author":"F Zhou","year":"2019","unstructured":"Zhou F, et al. Unexpected Rapid increase in the Burden of NAFLD in China from 2008 to 2018: a systematic review and Meta-analysis. Hepatology (Baltimore MD). 2019;70(4):1119\u201333.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"6","key":"3160_CR3","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/hep.27406","volume":"60","author":"F-S Wang","year":"2014","unstructured":"Wang F-S, et al. The global burden of liver disease: the major impact of China. Hepatology (Baltimore MD). 2014;60(6):2099\u2013108.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"2","key":"3160_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000443344","volume":"9","author":"EASL-EASD","year":"2016","unstructured":"EASL-EASD-. EASO Clinical Practice guidelines for the management of non-alcoholic fatty liver disease. Obes Facts. 2016;9(2):65\u201390.","journal-title":"Obes Facts"},{"issue":"1","key":"3160_CR5","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/hep.24376","volume":"54","author":"AJ Sanyal","year":"2011","unstructured":"Sanyal AJ, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (Baltimore MD). 2011;54(1):344\u201353.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"8","key":"3160_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3109\/07853890.2010.518623","volume":"43","author":"G Musso","year":"2011","unstructured":"Musso G, et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43(8):617\u201349.","journal-title":"Ann Med"},{"issue":"2","key":"3160_CR7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0168-8278(86)80075-7","volume":"2","author":"F Piccinino","year":"1986","unstructured":"Piccinino F, et al. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol. 1986;2(2):165\u201373.","journal-title":"J Hepatol"},{"issue":"10","key":"3160_CR8","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1111\/j.1572-0241.2002.06038.x","volume":"97","author":"A Regev","year":"2002","unstructured":"Regev A, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97(10):2614\u20138.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"3160_CR9","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/hep.24452","volume":"54","author":"R Hernaez","year":"2011","unstructured":"Hernaez R, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology (Baltimore MD). 2011;54(3):1082\u201390.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"10","key":"3160_CR10","doi-asserted-by":"publisher","first-page":"e00081","DOI":"10.14309\/ctg.0000000000000081","volume":"10","author":"G Ferraioli","year":"2019","unstructured":"Ferraioli G, et al. Detection of liver steatosis with a Novel Ultrasound-based technique: a pilot study using MRI-Derived Proton Density Fat Fraction as the Gold Standard. Clin Translational Gastroenterol. 2019;10(10):e00081.","journal-title":"Clin Translational Gastroenterol"},{"issue":"1","key":"3160_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00330-010-1905-5","volume":"21","author":"AE Bohte","year":"2011","unstructured":"Bohte AE, et al. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol. 2011;21(1):87\u201397.","journal-title":"Eur Radiol"},{"issue":"1","key":"3160_CR12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1148\/radiol.12110673","volume":"264","author":"SM Noworolski","year":"2012","unstructured":"Noworolski SM, et al. Liver steatosis: concordance of MR imaging and MR spectroscopic data with histologic grade. Radiology. 2012;264(1):88\u201396.","journal-title":"Radiology"},{"issue":"11","key":"3160_CR13","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ultrasmedbio.2010.07.005","volume":"36","author":"M Sasso","year":"2010","unstructured":"Sasso M, et al. Controlled attenuation parameter (CAP): a novel VCTE\u2122 guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36(11):1825\u201335.","journal-title":"Ultrasound Med Biol"},{"issue":"2","key":"3160_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.5009\/gnl15155","volume":"10","author":"JM Ahn","year":"2016","unstructured":"Ahn JM, et al. Relationship between controlled attenuation parameter and Hepatic Steatosis as assessed by Ultrasound in alcoholic or nonalcoholic fatty liver disease. Gut Liver. 2016;10(2):295\u2013302.","journal-title":"Gut Liver"},{"issue":"5","key":"3160_CR15","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.jhep.2013.12.018","volume":"60","author":"V de L\u00e9dinghen","year":"2014","unstructured":"de L\u00e9dinghen V, et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol. 2014;60(5):1026\u201331.","journal-title":"J Hepatol"},{"issue":"1","key":"3160_CR16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/jgh.13857","volume":"33","author":"VW-S Wong","year":"2018","unstructured":"Wong VW-S, et al. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33(1):70\u201385.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"3160_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/MCG.0b013e3181a84b8d","volume":"44","author":"M Friedrich-Rust","year":"2010","unstructured":"Friedrich-Rust M, et al. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers. J Clin Gastroenterol. 2010;44(1):58\u201365.","journal-title":"J Clin Gastroenterol"},{"key":"3160_CR18","first-page":"107","volume":"7","author":"J Wilder","year":"2014","unstructured":"Wilder J, Patel K. The clinical utility of FibroScan(\u00ae) as a noninvasive diagnostic test for liver disease. Med Devices (Auckland N Z). 2014;7:107\u201314.","journal-title":"Med Devices (Auckland N Z)"},{"issue":"4","key":"3160_CR19","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1002\/hep.29639","volume":"67","author":"C Caussy","year":"2018","unstructured":"Caussy C, et al. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology (Baltimore MD). 2018;67(4):1348\u201359.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"4","key":"3160_CR20","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jhep.2020.05.040","volume":"73","author":"L-Y Mak","year":"2020","unstructured":"Mak L-Y, et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J Hepatol. 2020;73(4):800\u20136.","journal-title":"J Hepatol"},{"issue":"5","key":"3160_CR21","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/MEG.0b013e328326792e","volume":"21","author":"M Minakari","year":"2009","unstructured":"Minakari M, et al. Liver steatosis in patients with chronic hepatitis B infection: host and viral risk factors. Eur J Gastroenterol Hepatol. 2009;21(5):512\u20136.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3160_CR22","doi-asserted-by":"crossref","unstructured":"Abenavoli L et al. Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study Medicina (Kaunas, Lithuania), 2023. 59(11).","DOI":"10.3390\/medicina59111935"},{"issue":"4","key":"3160_CR23","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1055\/s-0028-1091983","volume":"28","author":"A Wieckowska","year":"2008","unstructured":"Wieckowska A, Feldstein AE. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis. 2008;28(4):386\u201395.","journal-title":"Semin Liver Dis"},{"issue":"5","key":"3160_CR24","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s10620-016-4037-1","volume":"61","author":"S Kinner","year":"2016","unstructured":"Kinner S, Reeder SB, Yokoo T. Quantitative imaging biomarkers of NAFLD. Dig Dis Sci. 2016;61(5):1337\u201347.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"3160_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1148\/radiol.10091790","volume":"256","author":"JR van Werven","year":"2010","unstructured":"van Werven JR, et al. Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy. Radiology. 2010;256(1):159\u201368.","journal-title":"Radiology"},{"issue":"6","key":"3160_CR26","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3109\/00365528309182089","volume":"18","author":"M Pamilo","year":"1983","unstructured":"Pamilo M, et al. Evaluation of liver steatotic and fibrous content by computerized tomography and ultrasound. Scand J Gastroenterol. 1983;18(6):743\u20137.","journal-title":"Scand J Gastroenterol"},{"issue":"2","key":"3160_CR27","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1148\/radiol.12120896","volume":"267","author":"A Tang","year":"2013","unstructured":"Tang A, et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology. 2013;267(2):422\u201331.","journal-title":"Radiology"},{"issue":"6","key":"3160_CR28","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/j.1478-3231.2012.02781.x","volume":"32","author":"RP Myers","year":"2012","unstructured":"Myers RP, et al. Controlled attenuation parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver International: Official J Int Association Study Liver. 2012;32(6):902\u201310.","journal-title":"Liver International: Official J Int Association Study Liver"},{"issue":"1","key":"3160_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.15403\/jgld.2014.1121.mlp","volume":"24","author":"M Lup\u0219or-Platon","year":"2015","unstructured":"Lup\u0219or-Platon M, et al. Diagnostic accuracy of controlled attenuation parameter measured by transient elastography for the non-invasive assessment of liver steatosis: a prospective study. J Gastrointest Liver Diseases: JGLD. 2015;24(1):35\u201342.","journal-title":"J Gastrointest Liver Diseases: JGLD"},{"issue":"5","key":"3160_CR30","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","volume":"66","author":"T Karlas","year":"2017","unstructured":"Karlas T, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022\u201330.","journal-title":"J Hepatol"},{"issue":"12","key":"3160_CR31","doi-asserted-by":"publisher","first-page":"p863","DOI":"10.1016\/j.dld.2009.04.002","volume":"41","author":"C Stasi","year":"2009","unstructured":"Stasi C, et al. Transient elastography for the assessment of liver fibrosis in patients with chronic viral hepatitis: the missing tool? Dig Liver Disease: Official J Italian Soc Gastroenterol Italian Association Study Liver. 2009;41(12):p863\u2013866.","journal-title":"Dig Liver Disease: Official J Italian Soc Gastroenterol Italian Association Study Liver"},{"issue":"2","key":"3160_CR32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.21037\/atm-22-5821","volume":"11","author":"M Jiang","year":"2023","unstructured":"Jiang M, et al. The diagnostic value of novel ultrasound attenuation analysis in detecting liver steatosis identified by the controlled attenuation parameter: a diagnostic accuracy study. Annals Translational Med. 2023;11(2):38.","journal-title":"Annals Translational Med"},{"key":"3160_CR33","doi-asserted-by":"crossref","unstructured":"Taru M-G et al. How to Identify Advanced Fibrosis in Adult Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Using Ultrasound Elastography-A Review of the Literature and Proposed Multistep Approach Diagnostics (Basel, Switzerland), 2023. 13(4).","DOI":"10.3390\/diagnostics13040788"},{"key":"3160_CR34","doi-asserted-by":"crossref","unstructured":"Petroff D, et al. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. Volume 6. The Lancet. Gastroenterology & Hepatology; 2021. pp. 185\u201398. 3.","DOI":"10.1016\/S2468-1253(20)30357-5"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03160-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-024-03160-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03160-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T07:05:08Z","timestamp":1708931108000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-024-03160-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3160"],"URL":"https:\/\/doi.org\/10.1186\/s12876-024-03160-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3848781\/v1","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"9 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the institutional review board of the Shenzhen People\u2019s Hospital(LL-KY-2020310). This study obtained the informed consent of all patients. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This study has obtained written informed consent from all research participants for the publication of their clinical details or identifiable data, including clinical images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}